News

The financing was led by new investor New Enterprise Associates (NEA), a global healthcare and technology venture capital firm, with additional new participation from Kaiser Permanente Ventures, an

The appointment increases the board to six members, five of whom are non-employee directors. Mr Brooksby is currently CFO of InNexus Biotechnical, a publicly traded drug development company.

Echo’s Symphony transdermal continuous glucose monitoring (tCGM) system is in late-stage development for both the diabetes home use and hospital critical care settings. Symphony incorporates Echo’s new Prelude

Pirfenidone was developed in Japan for the treatment of idiopathic pulmonary fibrosis (IPF) by Shionogi, which has rights to pirfenidone in Japan, Taiwan and South Korea. InterMune has

A study is currently being conducted in the US wherein the site is actively screening and enrolling subjects. The protocol for the study is an open-label, two-treatment, two-period,

MedImmune will receive an upfront payment and has the potential to receive royalties on certain vaccine stockpiles or sales of other influenza products developed using the reverse genetics

Under the terms of the agreement, Philips and Celsion will collaborate to explore the potential for using Philips’s investigational magnetic resonance imaging-guided high intensity focused ultrasound (HIFU) system

Most recently, Mr Orville served as vice president of global sales for NextGen Sciences, an Ann Arbor, Michigan-based biomarker testing provider. Prior to joining NextGen, Mr Orville was

Under the terms of the agreement, Valeant purchased all of the outstanding shares of Coria from parent company, DFB Pharmaceuticals, and other shareholders for $95 million.